Furthermore, we found that CLEC19A overexpression reduced MMP2 activity through increased expression of TIMP3 and RECK. These results suggest that overexpression of CLEC19A significantly reduces the potential migration of GBM cancer cells by inhibiting the genes involved in the migration pathway. The gene discussed is MMP2; the disease is cancer.